Why ImmunityBio Stock Is Skyrocketing Again Today

Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible slate of good news. This morning, the company announced two bits of great news. First, enrollment for the company's Anktiva therapy exceeded expectations in a trial when treating non-muscle-invasive bladder cancer. This development means ImmunityBio could submit a biologics licensing agreement to the FDA by year's end.Second, another clinical trial showed that the company's CAR-NK therapy demonstrated 100% disease control in its first four patients with Non-Hodgkin lymphoma. This update could have significant, longer-term implications for ImmunityBio as it develops next-gen therapies beyond its first hit, Anktiva.These fantastic updates occur just:Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool